Rob joined the Board at its incorporation on 10 April 2012. He is Chief Financial Officer and Company Secretary and joined Itaconix (U.K.) Limited* in September 2008 from Renovo Group PLC where he spent seven years as Executive Director of Finance and Business Development. He was part of the Renovo management team that successfully took the company from a start-up organisation through to IPO on the Official List in London, and executed a significant licence of its lead drug to, and equity investment by, the Shire Pharmaceuticals Group. He began his career at Coopers & Lybrand Deloitte, before moving on to senior transactional roles at Enskilda Securities and senior finance and transactional roles at GlaxoWellcome and GlaxoSmithKline. He is currently serving as a Non-executive Director of the natural micro-encapsulation company Eden Research PLC. Rob has an MA from the University of Oxford and is a Fellow of the Institute of Chartered Accountants in England and Wales.
* Itaconix (U.K.) Limited is the operating subsidiary of Itaconix plc